Dr. Carolyn Owen is an Assistant Professor in the Division of Hematology & Hematological Malignancies. Her prior translational research is focused on the genetics of familial hematological malignancies but current clinical and research interests are chronic lymphocytic leukemia (CLL) and other lymphomas. She has a strong interest in clinical trials and is the local principal investigator for several studies in CLL.
Owen, Carolyn
Hematologic Oncology
Associate Professor
Web Presence:
Biography
Area of Focus
Summary of Research
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. NEJM 2014; 370:1101-10.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, et al. Ibrutinib vs Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia. NEJM 2015; 373(25):2425-37.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. NEJM 2017; 377: 1331-1344.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, Owen C, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. NEJM 2018; 378: 1107-1120.
Woyach JA, Rupper AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. NEJM 2018; 379: 2517-2528
Area Of Focus
Summary Of Research
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. NEJM 2014; 370:1101-10.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, et al. Ibrutinib vs Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia. NEJM 2015; 373(25):2425-37.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. NEJM 2017; 377: 1331-1344.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, Owen C, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. NEJM 2018; 378: 1107-1120.
Woyach JA, Rupper AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. NEJM 2018; 379: 2517-2528